≡

Multiplex Assay Kit for Neurofilament, Light Polypeptide (NEFL) ,etc. by FLIA (Flow Luminescence Immunoassay)

CMT1F; CMT2E; NF-L; NF68; NFL; 68 kDa neurofilament protein; Neurofilament triplet L protein

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Neurofilament, Light Polypeptide (NEFL) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Neurofilament, Light Polypeptide (NEFL) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Neurofilament, Light Polypeptide (NEFL) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Neurofilament, Light Polypeptide (NEFL) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 93-101 96
EDTA plasma(n=5) 89-96 92
heparin plasma(n=5) 93-101 97

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Neurofilament, Light Polypeptide (NEFL) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Neurofilament, Light Polypeptide (NEFL) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Neurofilament, Light Polypeptide (NEFL) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 90-97% 87-99% 95-105% 79-94%
EDTA plasma(n=5) 78-94% 78-97% 82-99% 80-93%
heparin plasma(n=5) 96-105% 83-96% 92-101% 88-99%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:NEFL) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 50μL standard or sample to each well,
    add 10μL magnetic beads,and 50μL Detection Reagent A,incubate 60min at 37°C on shaker;
3. Wash plate on magnetic frame for three times;
4. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
5. Wash plate on magnetic frame for three times;
6. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Acta Neurologica Scandinavica Effect of carotid endarterectomy on brain damage markers Pubmed:27126899
Acta Neurologica Scandinavica Effect of carotid endarterectomy on brain damage markers. pubmed:27126899
journal of neuroimmunology Cytokines and biological markers in autoimmune GFAP astrocytopathy: The potential role for pathogenesis and therapeutic implications Pubmed: 31254929
Cerebellum Neurofilament Light Chain Is a Biomarker of Neurodegeneration in Ataxia Telangiectasia 33893614
Medicine (Baltimore) Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis 34678870
J Clin Med Fatty Acid-Binding Protein 7 (FABP-7), Glutamic Acid and Neurofilament Light Chain (NFL) as Potential Markers of Neurodegenerative Disorders in Psoriatic Patients … Pubmed:35566558
Catalog No. Related products for research use of Oryctolagus cuniculus (Rabbit) Organism species Applications (RESEARCH USE ONLY!)
CEE038Rb ELISA Kit for Neurofilament, Light Polypeptide (NEFL) Enzyme-linked immunosorbent assay for Antigen Detection.
LME038Rb Multiplex Assay Kit for Neurofilament, Light Polypeptide (NEFL) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.